{"slideshow_credits": null, "snippet": "The money spent to influence doctors tends to be in the service of newer drugs that are &#8220;fairly redundant.&#8221;", "abstract": "The Upshot; ProPublica analysis of information contained in database known as Open Payments shows that drugs most aggressively marketed to doctors are not typically cures or medical breakthroughs, but new drugs that manufacturers hope will gain foothold; analysis is first comprehensive examination of how much money drug companies have spent in working with doctors.", "section_name": "The Upshot", "print_page": "3", "document_type": "article", "byline": {"person": [{"firstname": "Charles", "role": "reported", "lastname": "ORNSTEIN", "rank": 1, "organization": ""}, {"lastname": "JONES", "rank": 2, "firstname": "Ryann", "role": "reported", "organization": "", "middlename": "Grochowski"}], "original": "By CHARLES ORNSTEIN and RYANN GROCHOWSKI JONES", "contributor": ""}, "web_url": "http://www.nytimes.com/2015/01/08/upshot/the-drugs-that-companies-promote-to-doctors-are-rarely-breakthroughs.html", "lead_paragraph": "The money spent to influence doctors tends to be in the service of newer drugs that are &#8220;fairly redundant.&#8221;", "headline": {"print_headline": "Analyzing Drugs That Are Most Promoted to Doctors", "main": "The Drugs That Companies Promote to Doctors Are Rarely Breakthroughs", "content_kicker": "Public Health", "kicker": "The Upshot"}, "_id": "54ad823a38f0d817e02e6e46", "word_count": "1314", "multimedia": [{"height": 126, "url": "images/2015/01/14/upshot/08UP--Drugs-1/08UP--Drugs-1-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/01/14/upshot/08UP--Drugs-1/08UP--Drugs-1-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2015/01/14/upshot/08UP--Drugs-1/08UP--Drugs-1-articleLarge.jpg", "legacy": {"xlarge": "images/2015/01/14/upshot/08UP--Drugs-1/08UP--Drugs-1-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/01/14/upshot/08UP--Drugs-1/08UP--Drugs-1-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/01/14/upshot/08UP--Drugs-1/08UP--Drugs-1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-01-08T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Doctors", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "ProPublica", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Hospitals", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Eliquis (Drug)", "is_major": "N", "rank": "5"}, {"name": "subject", "value": "Pradaxa (Drug)", "is_major": "N", "rank": "6"}], "blog": [], "subsection_name": null, "type_of_material": "News"}